Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Company ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

The agreement means Ro has become the first alternative to Lilly's recently launched LillyDirect direct-to-consumer (DTC) platform that will be able to offer the lower-cost version of Zepbound ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who’ve ...